Denise Yardley, MD | Authors

Articles

Enzalutamide Shows Promise in HR+ Breast Cancer

December 07, 2017

Denise Yardley, MD, senior investigator, Sarah Cannon Research Institute, discusses the results from a recent phase II trial evaluating exemestane with or without enzalutamide in patients with hormone receptor–positive breast cancer.

Results of the APHINITY Trial in HER2-Positive Breast Cancer

June 06, 2017

Denise Yardley, MD, senior investigator, Sarah Cannon Research Institute, discusses the APHINITY trial, which compared chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with HER2-positive early breast cancer.